<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182373</url>
  </required_header>
  <id_info>
    <org_study_id>3357-101</org_study_id>
    <nct_id>NCT04182373</nct_id>
  </id_info>
  <brief_title>KW-3357 Study in Patients With Early Onset Severe Preeclampsia</brief_title>
  <official_title>A Phase 3, Randomized, Placebo-controlled, Double Blind Study of KW-3357 in Patients With Early Onset Severe Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyowa Kirin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Blood Products Organization</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyowa Kirin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of intravenous KW-3357 in patients with&#xD;
      early-onset severe preeclampsia by comparing the prolongation days of pregnancy with that of&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days of maintaining pregnancy</measure>
    <time_frame>Subjects will be observed until maternal and/or fetal indications for delivery necessitate cessation of expectant management or until approximately 34 0/7 weeks of gestation.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of achievement of 32 weeks of gestation</measure>
    <time_frame>28 days before the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of achievement of 34 weeks of gestation</measure>
    <time_frame>28 days before the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of achievement of 28 weeks of gestation in subjects enrolled in the period of less than 28 weeks of gestation</measure>
    <time_frame>28 days before the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AT activity</measure>
    <time_frame>From baseline to Day 8 at all time points and 3 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PLT concentration</measure>
    <time_frame>From baseline to Day 8 at all time points and 3 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change on D-dimer concentration</measure>
    <time_frame>From baseline to Day 8 at all time points</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FDP concentration</measure>
    <time_frame>From baseline to Day 8 at all time points</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sitting systolic blood pressure and sitting diastolic blood pressure</measure>
    <time_frame>From baseline to Day 8 at each time point, 3 days after termination of pregnancy, and 28 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria/creatinine ratio</measure>
    <time_frame>From baseline to Day 8 at each time point, 3 days after termination of pregnancy, and 28 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of blood lost during delivery</measure>
    <time_frame>28 days before the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biophysical Profile Score</measure>
    <time_frame>From baseline to Day 8 at each time point</time_frame>
    <description>Minimum is 0, max is 10. Higher score means better condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal growth rate</measure>
    <time_frame>28 days before the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apgar score</measure>
    <time_frame>At 1 minute and 5 minutes after birth</time_frame>
    <description>Minimum is 0, max is 10. Higher score means better condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of neonatal asphyxia</measure>
    <time_frame>At 1 minute and 5 minutes after birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth weight</measure>
    <time_frame>28 days before the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal growth</measure>
    <time_frame>28 days before the end of study</time_frame>
    <description>Fetal growth is classified into small for gestational age (SGA), appropriate for gestational age (AGA), and large for gestational age (LGA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head and chest circumferences at birth</measure>
    <time_frame>28 days before the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term prognosis of neonates (incidence of bronchopulmonary dysplasia, intraventricular hemorrhage, periventricular leukolame, retinopathy of prematurity, sepsis, necrotizing enteritis, death, etc)</measure>
    <time_frame>28 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of neonates who was hospitalized in the NICU</measure>
    <time_frame>28 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days in the NICU</measure>
    <time_frame>28 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of neonates with respiratory management at the time of admission to the NICU</measure>
    <time_frame>28 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of days of respiratory management at the time of admission to the NICU</measure>
    <time_frame>28 days after termination of pregnancy</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in TNF-alpha at the time of examination</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in interleukin (IL)-6 at the time of examination</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in IL-10 at the time of examination</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in hs-CRP at the time of examination</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in sFlt-1 at the time of examination</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in PlGF at the time of examination</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in sFlt-1/PlGF at the time of examination</measure>
    <time_frame>From baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Pulsatility index of the umbilical artery and middle cerebral artery</measure>
    <time_frame>At the time of examination from baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in findings of the umbilical artery and middle cerebral artery</measure>
    <time_frame>At the time of examination from baseline to Day 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Distribution of reasons for termination of pregnancy</measure>
    <time_frame>28 days before the end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Prolongation days of pregnancy by reason of termination of pregnancy</measure>
    <time_frame>28 days before the end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mode of delivery</measure>
    <time_frame>28 days before the end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence or absence of stillbirth</measure>
    <time_frame>28 days before the end of study. Neonates will be assessed after delivery.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Placental weight</measure>
    <time_frame>28 days before the end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence or absence of placental infarction</measure>
    <time_frame>28 days before the end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Umbilical arterial blood gas at termination of pregnancy</measure>
    <time_frame>28 days before the end of study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Presence or absence of HELLP syndromes and onset of symptoms</measure>
    <time_frame>During the course of the clinical trial. Period from the day of commencement of administration of the investigational drug to Day 28 after the delivery</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Preeclampsia</condition>
  <arm_group>
    <arm_group_label>KW-3357</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>72 IU/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithrombin gamma</intervention_name>
    <description>Intravenous infusion, once a day, 7 days</description>
    <arm_group_label>KW-3357</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>physiological saline</intervention_name>
    <description>Intravenous infusion, once a day, 7 days</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who gave written consent to participate in the clinical trial by their own&#xD;
             free will.&#xD;
&#xD;
          2. Patients aged 20 years or older at the time of obtaining informed consent&#xD;
&#xD;
          3. Patients with early-onset PE* 24 weeks 0 days to 31 weeks 6 days of gestation at the&#xD;
             time of enrollment&#xD;
&#xD;
             *: Determine the definition of gestational age based on the &quot;Guidelines for Obstetrics&#xD;
             and Gynecology, Obstetrics, 2017&quot;&#xD;
&#xD;
          4. Patients diagnosed with severe PE*&#xD;
&#xD;
             *: Follow the diagnostic criteria of the Japan Society for the Study of Hypertension&#xD;
             in Pregnancy&#xD;
&#xD;
          5. Patients with AT activity of 100% or less in the preliminary examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are judged to require immediate delivery*&#xD;
&#xD;
             *&quot;Best Practice Guide 2015 for Care and Treatment of Hypertension in Pregnancy&quot;&#xD;
             Requirements for Considering Pregnancy Termination Regardless of Pregnancy Weeks in&#xD;
             Pregnancy-induced Hypertension Syndrome Cases will be consulted for judgment.&#xD;
&#xD;
          2. Patients with right hypochondralgia or epigastralgia&#xD;
&#xD;
          3. Patients with HELLP syndromes&#xD;
&#xD;
          4. Patients with pulmonary edema&#xD;
&#xD;
          5. Patients with severe pleural effusion, severe ascites, or serous retinal detachment&#xD;
&#xD;
          6. Patients with central nervous system disorders (eclampsia, stroke) or visual disorders&#xD;
             (cortical blindness)&#xD;
&#xD;
          7. Patients with severe headache or urge eclampsia&#xD;
&#xD;
          8. Patients with abruptio placentae&#xD;
&#xD;
          9. Suspected patients with 8 or more obstetric DIC scores&#xD;
&#xD;
         10. Patients with a definitive diagnosis of congenital AT deficiency&#xD;
&#xD;
         11. Patients with diseases or symptoms other than the primary disease requiring immediate&#xD;
             delivery&#xD;
&#xD;
         12. Patients on ongoing treatment with nonsteroidal anti-inflammatory drugs (NSAIDs, e.g.,&#xD;
             aspirin) or who require NSAIDs use during the course of the study.&#xD;
&#xD;
         13. Patients who have received the following drugs within 72 hours before administration&#xD;
             of the investigational product, etc., or who require administration of the following&#xD;
             drugs during the study period (from the start of administration of the investigational&#xD;
             product, etc., until the date of termination of pregnancy); heparin,&#xD;
             low-molecular-weight heparin (e.g., enoxaparin or dalteparin), fondaparinux,&#xD;
             antiplatelet drugs (e.g., clopidogrel, prasugrel, aspirin), direct thrombin inhibitors&#xD;
             (e.g., dabigatran), or anticoagulants (e.g., AT preparations).&#xD;
&#xD;
         14. Patients with a current or past history of serious drug allergy&#xD;
&#xD;
         15. Patients with a history or complication of drug dependence or alcoholism&#xD;
&#xD;
         16. Patients with hypersensitivity to AT preparations&#xD;
&#xD;
         17. Patients who are pregnant with a fetus with a chromosomal abnormality or a fetus&#xD;
             suspected of having a serious malformation syndrome&#xD;
&#xD;
         18. Patients with multiple pregnancies&#xD;
&#xD;
         19. Patients with a history or complication of antiphospholipid antibody syndrome&#xD;
&#xD;
         20. Patients with diabetes complicated pregnancy, obvious diabetes mellitus, or insulin&#xD;
             use&#xD;
&#xD;
         21. Patients with uncontrollable or significant complications, including the following&#xD;
&#xD;
               -  Clinically significant cardiovascular diseases, etc. (New York Heart Association&#xD;
                  cardiac function classifications Class III or higher)&#xD;
&#xD;
               -  Serious hepatic disease&#xD;
&#xD;
               -  Serious renal disease&#xD;
&#xD;
               -  Pneumonia, interstitial lung disease or other severe respiratory disease&#xD;
&#xD;
               -  Blood disorders such as idiopathic thrombocytopenic purpura&#xD;
&#xD;
               -  Psycho-central nervous system disorders that may affect informed consent&#xD;
&#xD;
               -  Endocrine disorders such as hyperthyroidism&#xD;
&#xD;
               -  Autoimmune diseases such as systemic lupus erythematosus&#xD;
&#xD;
         22. Patients with active malignancy or patients with a history of onset or treatment of&#xD;
             malignancy within 5 years before pregnancy (excluding excised or surgically cured&#xD;
             basal cell carcinoma of the skin, squamous cell carcinoma of the skin or ductal&#xD;
             carcinoma of the breast)&#xD;
&#xD;
         23. Patients with active infections (e.g., toxoplasma infection, genital chlamydia,&#xD;
             genital herpes, cytomegalovirus infection)&#xD;
&#xD;
         24. Patients with a positive history for HIV antibody. Patients with a positive history&#xD;
             for HBs antigen and HCV antibody and with active infection presenting with hepatitis&#xD;
             symptoms.&#xD;
&#xD;
         25. Patients with any of the following laboratory abnormalities in preliminary&#xD;
             examinations; Patients with AST or ALT 2 times the upper limit of the reference level&#xD;
             of the trial site; Cr &gt;=1.1 mg/dL&#xD;
&#xD;
         26. Patients who have participated in a clinical trial or equivalent study of a drug or&#xD;
             medical device within 4 months before pregnancy (within 6 months for biologics) and&#xD;
             have received the investigational drug or used an unapproved medical device&#xD;
&#xD;
         27. Other patients whom the principal investigator or the subinvestigator judges to be&#xD;
             unfavorable for participation in the clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kyowa Kirin Co., Ltd</last_name>
    <phone>+81-3-5205-7200</phone>
    <email>clinical.info.jp@kyowakirin.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Japanese Red Cross Nagoya Daiichi Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fujita Health University Hospital</name>
      <address>
        <city>Toyoake</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toyota Memorial Hospital</name>
      <address>
        <city>Toyota</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juntendo University Urayasu Hospital</name>
      <address>
        <city>Urayasu</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Yachiyo Medical Center</name>
      <address>
        <city>Yachiyo</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ehime University Hospital</name>
      <address>
        <city>Toon</city>
        <state>Ehime</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kokura Medical Center</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Snow Social Medical Corporation St. Mary's Hospital</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hakodate Central General Hospital</name>
      <address>
        <city>Hakodate</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Obihiro Kosei General Hospital</name>
      <address>
        <city>Obihiro</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sapporo City General Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Society Himeji Hospital</name>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kobe University Hospital</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ishikawa Prefectural Central Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Medical Center for Children and Adults</name>
      <address>
        <city>Zentsuji</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Kitasato Institute Kitasato University Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sendai Red Cross Hospital</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagasaki Medical Center</name>
      <address>
        <city>Omura</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okinawa prefectural Chubu Hospital</name>
      <address>
        <city>Uruma</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Abeno-ku</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rinku General Medical Center</name>
      <address>
        <city>Izumisano</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka Women's and Children's Hospital</name>
      <address>
        <city>Izumi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Medical Center</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamamatsu Medical Center</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University Hospital</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juntendo University Shizuoka Hospital</name>
      <address>
        <city>Izunokuni</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dokkyo Medical University Hospital</name>
      <address>
        <city>Mibu</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Tama Medical Center</name>
      <address>
        <city>Fuchu</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aiiku Hospital</name>
      <address>
        <city>Minato</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital</name>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Center for Child Health and Development</name>
      <address>
        <city>Setagaya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Medical Center</name>
      <address>
        <city>Shibuya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Showa University Hospital</name>
      <address>
        <city>Shinagawa</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Bokutoh Hospital</name>
      <address>
        <city>Sumida</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yamaguchi University Hospital</name>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yamanashi Prefectural Central Hospital</name>
      <address>
        <city>Kofu</city>
        <state>Yamanashi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aomori Prefectural Central Hospital</name>
      <address>
        <city>Aomori</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukuoka University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kagoshima City Hospital</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kumamoto University Hospital</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine, University of Miyazaki Hospital</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nara Prefecture General Medical Center</name>
      <address>
        <city>Nara</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical &amp; Dental Hospital</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oita Prefectural Hospital</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Toyama University Hospital</name>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>Antithrombin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

